Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Castle Biosciences ( (CSTL) ) just unveiled an announcement.
Castle Biosciences reported a robust third quarter for 2024, with revenues surging by 39% to $86 million and a 41% increase in total test reports compared to the same quarter last year. The company attributes this success to the strong adoption of their diagnostic tests, driven by enhanced clinical evidence, particularly for DecisionDx®-SCC and other core products. Castle Biosciences has raised its full-year revenue guidance, projecting significant growth and profitability, showcasing the effectiveness of their business model and dedication to creating value for patients, clinicians, and shareholders.
Find detailed analytics on CSTL stock on TipRanks’ Stock Analysis page.